Smart Patients’ Post

Tirzepatide-Induced Rapid Weight Loss–Related Thyrotoxicosis - - We are continually reminded about the potency of emerging Incretin and NuSH-based therapies. Every day I see several patients that churned out “set it and forget it” clinics due to bad experiences. Looking forward to the discussion at #OW2024. https://t.co/9dXTg5nErd

Learn how our smart technology gathers, analyses and reports information which aids in the decision-making and clinical action throughout the colorectal pathway, from diagnosis to follow-up. #medtronicemployee #MedtronicEmployee

How can IVD blood tests help to improve outcomes for Alzheimer’s patients? Find out more: https://lnkd.in/dsYwCZbE #AlzheimersDisease #AlzheimersTesting #IVDbloodtests

Clinical benefit in the Bria-IMT™ Phase 1/2 study was seen in 55% of evaluable patients across all subtypes of #breastcancer as shown in Figure 2 below. Learn more: https://bit.ly/3KsI9hV #ASCO24 #metastaticbreastcancer

A patient-centric approach is crucial when developing therapies for complex diseases like #MultipleMyeloma, but patients still struggle to be heard. Learn how actively involving patients across the product lifecycle will drive more successful launches and ultimately improve outcomes, transforming patients’ lives: https://bit.ly/3xRmahJ #PatientExperienceWeek #WeAreAvalereHealth #AvalereHealth

The Primary Carer's role extends beyond detection and referral, to include patient management. However, monoclonal gammopathies are a spectrum of conditions that many Primary Care Providers (PCP) may not be familiar with and may feel uncomfortable managing patients. The Primary Care’s involvement in patient management will vary with the type of monoclonal gammopathy involved. Professor Spencer offered his thoughts on this and gave some helpful advice for PCPs when monitoring patients with monoclonal gammopathy of undetermined significance (MGUS). Learn more: https://hubs.li/Q02XHlJf0 #MultipleMyeloma #Diagnosis

Clinical benefit in the Bria-IMT™ Phase 1/2 study was seen in 55% of evaluable patients across all subtypes of #breastcancer as shown in Figure 2 below. Learn more: https://bit.ly/3KsI9hV #ASCO24 #metastaticbreastcancer

The clinical data BriaCell presented at #ASCO24 shows that Bria-IMT™ offers extended progression-free survival and clinical benefit in heavily pre-treated, ADC resistant #breastcancer patients versus those in other similar studies. Learn more: https://bit.ly/3KsI9hV #metastaticbreastcancer

The prevalence of sepsis need to be controlled by timely diagnosis and monitoring of Procalcitonin. The below blog gives you an overview of why diagnosis of Sepsis is important. #procalcitonin #sepsisawareness #sepsis DiaSys Diagnostics India Pvt Ltd DiaSys Diagnostic Systems GmbH

True that, Procalcitonin is biggest leading indicator for Sepsis. It can Show Traces of Severity of Sepsis too. Combined with PCR's can prove to be a Best Combination..